Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Résumé détaillé

Novartis (NVS) is ending the development of heart drug pelacarsen discovered by Ionis Pharmaceuticals (IONS) after a late-stage trial setback. Read more here.

Novartis (NVS) is largely abandoning the development of a heart disease therapy discovered by Ionis Pharmaceuticals (IONS) after the RNA-targeting therapy failed in a late-stage trial last September, Bloomberg reported on Saturday.

Début de l'article, extrait de Seeking Alpha. Pour lire la suite, ouvrez l'article chez le média.